NCT06066138View on ClinicalTrials.gov

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part SarcomaLocally Advanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung CancerLocally Advanced Small Cell Lung CancerMetastatic Small Cell Lung CancerLocally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaLocally Advanced MelanomaMetastatic Melanoma
Interventions
DRUG

Atezolizumab

Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH